Adaptimmune Therapeutics PLC: Adaptimmune Announces Initiati

- Afami-cel has the potential to be the first approved engineered TCR T-cell therapy for a solid tumor - -Synovial sarcoma has a high unmet medical need and the pivotal trial met its primary endpoint

Related Keywords

Pennsylvania , United States , Philadelphia , Dennis Williams , Julip Miller , Dana Lynch , Stage Development , Exchange Commission , Corporate Communications , Drug Administration , Corporate Affairs , Nasdaq , United Newsfile Corp , Biologics License Application , Specific Peptide Enhanced Affinity Receptor , Private Securities Litigation Reform Act , Annual Report , Quarterly Reports , Current Reports , Senior Director , Adaptimmune , Herapeutics , Nnounces , Initiation , Iologics , License , Application , Submission , Yfami , First , Engineered , Fell , Therapy , Targeting , Age , Treatment , Synovial , Tarcoma ,